MARC HOROWITZ to Antineoplastic Agents
This is a "connection" page, showing publications MARC HOROWITZ has written about Antineoplastic Agents.
Connection Strength
0.254
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
Score: 0.126
-
Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014 Mar; 16(3):457-65.
Score: 0.058
-
Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
Score: 0.017
-
Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
Score: 0.016
-
Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 01; 84(7):2221-8.
Score: 0.015
-
Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991 Apr; 9(4):600-5.
Score: 0.012
-
Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein. Am J Clin Pathol. 1986 Dec; 86(6):780-3.
Score: 0.009